Receptos Now Covered by Credit Suisse (RCPT)
Equities research analysts at Credit Suisse assumed coverage on shares of Receptos (NASDAQ:RCPT) in a research note issued to investors on Friday, AnalystRatingsNetwork reports. The firm set an “outperform” rating on the stock.
Receptos (NASDAQ:RCPT) opened at 35.50 on Friday. Receptos has a 1-year low of $13.00 and a 1-year high of $36.15. The stock’s 50-day moving average is $26.76 and its 200-day moving average is $23.24. The company’s market cap is $651.0 million.
Receptos (NASDAQ:RCPT) last posted its quarterly earnings results on Wednesday, October 30th. The company reported ($0.88) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.61) by $0.27. The company had revenue of $1.10 million for the quarter. On average, analysts predict that Receptos will post $-6.26 earnings per share for the current fiscal year.
Several other analysts have also recently commented on the stock. Analysts at Leerink Swann raised their price target on shares of Receptos to $45.00 in a research note to investors on Thursday, December 5th. Separately, analysts at Wedbush raised their price target on shares of Receptos to $44.00 in a research note to investors on Monday, November 18th. Finally, analysts at BMO Capital Markets reiterated an “outperform” rating on shares of Receptos in a research note to investors on Thursday, October 31st. They now have a $41.00 price target on the stock, up previously from $40.00.
In other Receptos news, Director William Rastetter sold 37,359 shares of Receptos stock in a transaction that occurred on Friday, January 3rd. The shares were sold at an average price of $30.85, for a total value of $1,152,525.15. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
Receptos, Inc (NASDAQ:RCPT) is a biopharmaceutical company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.